肠道病毒 A71 的抗病毒药物和疫苗。
Antivirals and vaccines for Enterovirus A71.
机构信息
Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City, Taiwan.
Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
出版信息
J Biomed Sci. 2019 Sep 3;26(1):65. doi: 10.1186/s12929-019-0560-7.
Abstract
Enterovirus A71 (EV-A71) is an important emerging virus posing a threat to children under five years old. EV-A71 infection in infants or young children can cause hand-foot-and-mouth disease, herpangina, or severe neurological complications. However, there are still no effective antivirals for treatment of these infections. In this review, we summarize the antiviral compounds developed to date based on various targets of the EV-A71 life cycle. Moreover, development of a vaccine would be the most effective approach to prevent EV-A71 infection. Therefore, we also summarize the development and clinical progress of various candidate EV-A71 vaccines, including inactivated whole virus, recombinant VP1 protein, synthetic peptides, viral-like particles, and live attenuated vaccines.
摘要
肠道病毒 A71 型（EV-A71）是一种重要的新兴病毒，对五岁以下儿童构成威胁。婴儿或幼儿感染 EV-A71 可引起手足口病、疱疹性咽峡炎或严重的神经并发症。然而，目前针对这些感染还没有有效的抗病毒药物。在这篇综述中，我们根据 EV-A71 生命周期的各种靶点，总结了迄今为止开发的抗病毒化合物。此外，疫苗的开发将是预防 EV-A71 感染最有效的方法。因此，我们还总结了各种候选 EV-A71 疫苗的开发和临床进展，包括灭活全病毒、重组 VP1 蛋白、合成肽、病毒样颗粒和减毒活疫苗。
相似文献
1
Antivirals and vaccines for Enterovirus A71.
J Biomed Sci. 2019 Sep 3;26(1):65. doi: 10.1186/s12929-019-0560-7.
2
Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
J Virol. 2019 Jun 14;93(13). doi: 10.1128/JVI.02308-18. Print 2019 Jul 1.
3
Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development.
Rev Inst Med Trop Sao Paulo. 2018 Nov 8;60:e70. doi: 10.1590/S1678-9946201860070.
4
A Polysaccharide Purified From Acts as a Potent Mucosal Adjuvant That Promotes Protective Immunity Against the Lethal Challenge With Enterovirus A71.
Front Immunol. 2020 Sep 29;11:561758. doi: 10.3389/fimmu.2020.561758. eCollection 2020.
5
Development of Novel miRNA-based Vaccines and Antivirals against Enterovirus 71.
Curr Pharm Des. 2016;22(44):6694-6700. doi: 10.2174/1381612822666160720165613.
6
Is a multivalent hand, foot, and mouth disease vaccine feasible?
Hum Vaccin Immunother. 2015;11(11):2688-704. doi: 10.1080/21645515.2015.1049780. Epub 2015 May 26.
7
Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Antiviral Res. 2017 Jan;137:67-75. doi: 10.1016/j.antiviral.2016.11.008. Epub 2016 Nov 15.
8
Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
Viral Immunol. 2016 Jun;29(5):288-95. doi: 10.1089/vim.2015.0110.
9
EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
Emerg Microbes Infect. 2016 Jul 20;5(7):e75. doi: 10.1038/emi.2016.73.
10
Development of Novel Vaccines against Enterovirus-71.
Viruses. 2015 Dec 30;8(1):1. doi: 10.3390/v8010001.
引用本文的文献
1
Epidemiological, etiological, and serological characteristics of hand, foot, and mouth disease in Guizhou Province, Southwest China, from 2008 to 2023.
PLoS Negl Trop Dis. 2025 Aug 18;19(8):e0013394. doi: 10.1371/journal.pntd.0013394. eCollection 2025 Aug.
2
Clinical characteristics of fatal cases of hand, foot and mouth disease in children.
Front Pediatr. 2025 Jul 17;13:1522164. doi: 10.3389/fped.2025.1522164. eCollection 2025.
3
A human intestinal organoid derived from fetal human colon cells model for studying enteroviral pathogenesis.
Virulence. 2025 Dec;16(1):2542455. doi: 10.1080/21505594.2025.2542455. Epub 2025 Aug 4.
4
Design of a Fluorescence Polarization Probe for Enterovirus 2C Proteins.
J Med Chem. 2025 Jul 10;68(13):14041-14053. doi: 10.1021/acs.jmedchem.5c01219. Epub 2025 Jun 21.
5
Insights into the mechanisms of apoptosis and pathogenesis in enterovirus 71 infections: A review.
Medicine (Baltimore). 2025 Apr 11;104(15):e42183. doi: 10.1097/MD.0000000000042183.
6
Targeting WDPF domain of Hsp27 achieves a broad spectrum of antiviral.
MedComm (2020). 2025 Feb 26;6(3):e70032. doi: 10.1002/mco2.70032. eCollection 2025 Mar.
7
A nucleoside-modified mRNA vaccine prevents enterovirus A71 infection in mouse model.
Front Immunol. 2025 Feb 12;16:1535758. doi: 10.3389/fimmu.2025.1535758. eCollection 2025.
8
Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy.
Front Immunol. 2025 Jan 14;15:1524356. doi: 10.3389/fimmu.2024.1524356. eCollection 2024.
9
Etoposide targets 2A protease to inhibit enterovirus 71 replication.
Microbiol Spectr. 2025 Jan 7;13(1):e0220024. doi: 10.1128/spectrum.02200-24. Epub 2024 Nov 18.
10
Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.
Vet Res. 2024 Sep 30;55(1):128. doi: 10.1186/s13567-024-01383-x.
本文引用的文献
1
and Inhibition of the Infectivity of Human Enterovirus 71 by a Sulfonated Food Azo Dye, Brilliant Black BN.
J Virol. 2019 Aug 13;93(17). doi: 10.1128/JVI.00061-19. Print 2019 Sep 1.
2
Recombinant lactococcus lactis secreting viral protein 1 of enterovirus 71 and its immunogenicity in mice.
Biotechnol Lett. 2019 Jul;41(6-7):867-872. doi: 10.1007/s10529-019-02695-1. Epub 2019 May 22.
3
Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
J Virol. 2019 Jun 14;93(13). doi: 10.1128/JVI.02308-18. Print 2019 Jul 1.
4
Mucosal vaccines and technology.
Clin Exp Immunol. 2019 May;196(2):205-214. doi: 10.1111/cei.13285. Epub 2019 Apr 8.
5
Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice.
Sci Rep. 2019 Mar 18;9(1):4805. doi: 10.1038/s41598-019-41285-z.
6
APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity.
Antiviral Res. 2019 May;165:23-33. doi: 10.1016/j.antiviral.2019.03.005. Epub 2019 Mar 9.
7
Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
Vaccine. 2019 Mar 22;37(13):1827-1835. doi: 10.1016/j.vaccine.2019.02.023. Epub 2019 Feb 22.
8
Monoclonal antibody against EV71 3D inhibits the polymerase activity of RdRp and virus replication.
BMC Immunol. 2019 Jan 22;20(1):6. doi: 10.1186/s12865-019-0288-x.
9
4-Iminooxazolidin-2-one as a Bioisostere of the Cyanohydrin Moiety: Inhibitors of Enterovirus 71 3C Protease.
J Med Chem. 2018 Nov 21;61(22):10333-10339. doi: 10.1021/acs.jmedchem.8b01335. Epub 2018 Nov 8.
10
MicroR-9-5p suppresses EV71 replication through targeting NFκB of the RIG-I-mediated innate immune response.
FEBS Open Bio. 2018 Aug 29;8(9):1457-1470. doi: 10.1002/2211-5463.12490. eCollection 2018 Sep.
Zotero 插件